Title of article :
Efficacy of Taxotere, Thalidomide, and Prednisolone in Patients with Hormone-Resistant Metastatic Prostate Cancer
Author/Authors :
Rezvani، Hamid نويسنده Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran , , Haghighi، Shirin نويسنده Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran , , Ghadyani، Mojtaba نويسنده Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran , , Attarian، Hamid نويسنده ,
Abstract :
Purpose: To evaluate the efficacy and safety of combination treatment with thalidomide and taxotere in patients with hormone-resistant prostate cancer.
Materials and Methods: This clinical trial was performed on 16 patients with hormone-resistant prostate cancer.
Results: Mean age of the participants was 72.7 ± 5.39 years (range, 65 to 85 years). In 94% of patients who received the drug combination, prostate-specific antigen level decreased more than 50%. The mean time to progression was 15 months and mean survival time was 23 months. This combination therapy has some adverse events.
Conclusion: Addition of anti-angiogenic agents, such as thalidomide, can improve therapeutic outcome in this group of patients.
